Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10143693 | JANSSEN PHARMS | Dosing regimen for missed doses for long-acting injectable paliperidone esters |
Apr, 2036
(12 years from now) | |
US11324751 | JANSSEN PHARMS | Dosing regimens associated with extended release paliperidone injectable formulations |
May, 2041
(17 years from now) | |
US11304951 | JANSSEN PHARMS | Dosing regimens associated with extended release paliperidone injectable formulations |
May, 2041
(17 years from now) | |
US11666697 | JANSSEN PHARMS | Methods for ensuring resuspension of paliperidone palmitate formulations |
Nov, 2041
(18 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Strength (NS) | Aug 30, 2024 |
Drugs and Companies using PALIPERIDONE PALMITATE ingredient
Market Authorisation Date: 18 May, 2015
Treatment: Reinitiation of schizophrenia treatment following a missed dose more than 9 months ago; Reinitiation of schizophrenia treatment following a missed dose 4-9 months ago; Treatment of schizophrenia by ad...
Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9439906 | JANSSEN PHARMS | Dosing regimen associated with long acting injectable paliperidone esters |
Jan, 2031
(7 years from now) |
Drugs and Companies using PALIPERIDONE PALMITATE ingredient
Market Authorisation Date: 31 July, 2009
Treatment: Treatment of schizophrenia; Treatment of schizoaffective disorder as a monotherapy and as an adjunct to mood stabilizers or antidepressants; Dosing regimen for the treatment of schizoaffective disorde...
Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7943788 | JANSSEN PHARMS | Glucopyranoside compound |
Jul, 2027
(3 years from now) | |
US8513202 | JANSSEN PHARMS | Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate |
Dec, 2027
(4 years from now) | |
US7943582 | JANSSEN PHARMS | Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate |
Feb, 2029
(5 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8785403 | JANSSEN PHARMS | Glucopyranoside compound |
Jul, 2024
(10 months from now) | |
US8222219 | JANSSEN PHARMS | Glucopyranoside compound |
Apr, 2025
(1 year, 6 months from now) | |
US11576894 | JANSSEN PHARMS | Combination therapy for the treatment of diabetes |
Jul, 2030
(6 years from now) |
Drugs and Companies using CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient
Market Authorisation Date: 08 August, 2014
Treatment: Reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients; Treatment of type 2 diabetes mellitus; Reduction of risk of end stage kidney disease, do...
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7943788 | JANSSEN PHARMS | Glucopyranoside compound |
Jul, 2027
(3 years from now) | |
US8513202 | JANSSEN PHARMS | Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate |
Dec, 2027
(4 years from now) | |
US7943582 | JANSSEN PHARMS | Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate |
Feb, 2029
(5 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8785403 | JANSSEN PHARMS | Glucopyranoside compound |
Jul, 2024
(10 months from now) | |
US8222219 | JANSSEN PHARMS | Glucopyranoside compound |
Apr, 2025
(1 year, 6 months from now) |
Drugs and Companies using CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient
Market Authorisation Date: 20 September, 2016
Treatment: Reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients; Treatment of type 2 diabetes mellitus; Reduction of risk of end stage kidney disease, do...
Dosage: TABLET, EXTENDED RELEASE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7943788 | JANSSEN PHARMS | Glucopyranoside compound |
Jul, 2027
(3 years from now) | |
US8513202 | JANSSEN PHARMS | Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate |
Dec, 2027
(4 years from now) | |
US7943582 | JANSSEN PHARMS | Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate |
Feb, 2029
(5 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8222219 | JANSSEN PHARMS | Glucopyranoside compound |
Apr, 2025
(1 year, 6 months from now) | |
US10617668 | JANSSEN PHARMS | Pharmaceutical formulations |
May, 2031
(7 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication (I) | Sep 27, 2022 |
Drugs and Companies using CANAGLIFLOZIN ingredient
Market Authorisation Date: 29 March, 2013
Treatment: Treatment of type 2 diabetes mellitus; Reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients; Reduction of risk of end stage kidney disease, do...
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6806256 | JANSSEN PHARMS | Taste masked liquid pharmaceutical compositions |
Feb, 2022
(1 year, 7 months ago) | |
US6806256 (Pediatric) | JANSSEN PHARMS | Taste masked liquid pharmaceutical compositions |
Aug, 2022
(1 year, 1 month ago) |
Drugs and Companies using LEVOFLOXACIN ingredient
Market Authorisation Date: 21 October, 2004
Treatment: NA
Dosage: SOLUTION;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
USRE43728 | JANSSEN PHARMS | Thiazolidin-4-one derivatives |
Nov, 2024
(1 year, 1 month from now) | |
US9062014 | JANSSEN PHARMS | Crystalline forms of (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-0-tolyl-thiazolidin-4-one |
May, 2032
(8 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9000018 | JANSSEN PHARMS | Thiazolidin-4-one-derivatives |
Nov, 2024
(1 year, 1 month from now) | |
US8273779 | JANSSEN PHARMS | Thiazolidin 4-one derivatives |
Dec, 2025
(2 years from now) | |
US10220023 | JANSSEN PHARMS | Dosing regimen for a selective S1P1 receptor agonist |
Dec, 2035
(12 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Mar 18, 2026 |
Drugs and Companies using PONESIMOD ingredient
NCE-1 date: 2025-03-18
Market Authorisation Date: 18 March, 2021
Treatment: Reduction of circulating lymphocytes in treating relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive dise...
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9592207 | JANSSEN PHARMS | Intranasal administration of ketamine to treat depression |
Mar, 2027
(3 years from now) | |
US8785500 | JANSSEN PHARMS | Intranasal administration of ketamine to treat depression |
Mar, 2033
(9 years from now) | |
US11446260 | JANSSEN PHARMS | Pharmaceutical composition of S-ketamine hydrochloride |
Mar, 2034
(10 years from now) | |
US11173134 | JANSSEN PHARMS | Methods for the treatment of depression |
Sep, 2035
(11 years from now) | |
US10869844 | JANSSEN PHARMS | Methods for the treatment of depression |
Sep, 2035
(11 years from now) | |
US11311500 | JANSSEN PHARMS | Methods for the treatment of depression |
Sep, 2035
(11 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
NCE* (NCE*) | Mar 5, 2024 |
New Indication (I) | Jul 31, 2023 |
Drugs and Companies using ESKETAMINE HYDROCHLORIDE ingredient
Market Authorisation Date: 05 March, 2019
Treatment: Treatment of treatment-resistant depression in adult in conjunction with an oral antidepressant; Treatment of depressive symptoms in adults with mdd with acute suicidal ideation or behavior by nasally...
Dosage: SPRAY;NASAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7157456 | JANSSEN PHARMS | Substituted oxazolidinones and their use in the field of blood coagulation |
Aug, 2024
(10 months from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9415053 | JANSSEN PHARMS | Solid, orally administrable pharmaceutical composition |
Nov, 2024
(1 year, 1 month from now) | |
US7157456 (Pediatric) | JANSSEN PHARMS | Substituted oxazolidinones and their use in the field of blood coagulation |
Feb, 2025
(1 year, 5 months from now) | |
US9415053 (Pediatric) | JANSSEN PHARMS | Solid, orally administrable pharmaceutical composition |
May, 2025
(1 year, 7 months from now) | |
US9539218 | JANSSEN PHARMS | Prevention and treatment of thromboembolic disorders |
Feb, 2034
(10 years from now) | |
US9539218 (Pediatric) | JANSSEN PHARMS | Prevention and treatment of thromboembolic disorders |
Aug, 2034
(10 years from now) | |
US10828310 | JANSSEN PHARMS | Reducing the risk of cardiovascular events |
Jan, 2039
(15 years from now) | |
US10828310 (Pediatric) | JANSSEN PHARMS | Reducing the risk of cardiovascular events |
Jul, 2039
(15 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication (I) | Aug 23, 2024 |
M (M) | Mar 10, 2023 |
Pediatric Exclusivity (PED) | Sep 10, 2023 |
Drugs and Companies using RIVAROXABAN ingredient
Market Authorisation Date: 01 July, 2011
Treatment: Reducing the risk of stroke and systemic embolism; Treatment of pulmonary embolism (pe); Treatment of deep vein thrombosis (dvt); Reduction of risk of major cardiovascular events (cv death, mi, and st...
Dosage: TABLET;ORAL
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic